RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility.
作者信息
Cravo Marilia
机构信息
Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal.
Faculdade de Medicina de Lisboa, Lisbon, Portugal.
出版信息
GE Port J Gastroenterol. 2016 Jan 19;23(1):1-3. doi: 10.1016/j.jpge.2015.12.004. eCollection 2016 Jan-Feb.
Abstract
摘要
相似文献
1
RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility.红细胞分布宽度作为活动期克罗恩病的替代标志物：潜在用途。
GE Port J Gastroenterol. 2016 Jan 19;23(1):1-3. doi: 10.1016/j.jpge.2015.12.004. eCollection 2016 Jan-Feb.
2
Value of red cell distribution width for assessing disease activity in Crohn's disease.红细胞分布宽度评估克罗恩病疾病活动度的价值。
Am J Med Sci. 2015 Jan;349(1):42-5. doi: 10.1097/MAJ.0000000000000334.
3
4
Assessment of Ileocolonic Inflammation in Crohn's Disease: Which Surrogate Marker Is Better-MaRIA, Clermont, or PET/MR Index? Initial Results of a Feasibility Trial.克罗恩病回肠结肠炎症评估：替代标志物中哪个更好——MARIA、Clermont 还是 PET/MR 指数？一项可行性试验的初步结果。
J Nucl Med. 2019 Jun;60(6):851-857. doi: 10.2967/jnumed.118.216937. Epub 2018 Nov 2.
5
Differential regulation of peripheral leukocyte genes in patients with active Crohn's disease and Crohn's disease in remission.活动性克罗恩病和缓解期克罗恩病患者外周血白细胞基因的差异调节。
J Clin Gastroenterol. 2010 Feb;44(2):120-6. doi: 10.1097/MCG.0b013e3181a9ef53.
6
Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease.粪便钙卫蛋白：影响其水平的因素及其作为克罗恩病发病风险替代标志物的潜在作用。
BMC Gastroenterol. 2016 Oct 7;16(1):126. doi: 10.1186/s12876-016-0535-z.
7
IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin.与针对甘露聚糖或鞭毛蛋白的IgG相比，针对常见肠道细菌的IgG抗体对克罗恩病更具诊断价值。
Am J Gastroenterol. 2008 Feb;103(2):386-96. doi: 10.1111/j.1572-0241.2007.01577.x. Epub 2007 Oct 9.
8
An evaluation of utility measurement in Crohn's disease.评估克罗恩病的效用测量。
Inflamm Bowel Dis. 1997 Winter;3(4):265-76.
9
Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy.生物治疗维持期克罗恩病患者的疾病转归与粪便钙卫蛋白水平的关联
Frontline Gastroenterol. 2014 Jul;5(3):167-175. doi: 10.1136/flgastro-2014-100441. Epub 2014 Apr 16.
10
Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
Aliment Pharmacol Ther. 2004 Oct 15;20(8):851-7. doi: 10.1111/j.1365-2036.2004.02097.x.
引用本文的文献
1
Hematological markers as prognostic indicators in multiple sclerosis progression.血液学标志物作为多发性硬化症进展的预后指标
Biomark Med. 2025 Jan;19(1):5-12. doi: 10.1080/17520363.2024.2441106. Epub 2024 Dec 17.
2
Red Cell Distribution Width as a Novel Prognostic Marker in Multiple Clinical Studies.红细胞分布宽度作为多项临床研究中的新型预后标志物。
Indian J Crit Care Med. 2020 Jan;24(1):49-54. doi: 10.5005/jp-journals-10071-23328.
本文引用的文献
1
Can Red Cell Distribution Width Be Used as a Marker of Crohn's Disease Activity?红细胞分布宽度能否用作克罗恩病活动的标志物？
GE Port J Gastroenterol. 2015 Nov 24;23(1):6-12. doi: 10.1016/j.jpge.2015.10.003. eCollection 2016 Jan-Feb.
2
Recent Directions in Telemedicine: Review of Trends in Research and Practice.远程医疗的最新发展方向：研究与实践趋势综述
Healthc Inform Res. 2015 Oct;21(4):213-22. doi: 10.4258/hir.2015.21.4.213. Epub 2015 Oct 31.
3
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.炎症性肠病治疗靶点选择（STRIDE）：确定达标治疗的治疗目标
Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25.
4
Immunosuppression in inflammatory bowel disease: how much is too much?炎症性肠病中的免疫抑制：多少算太多？
Curr Opin Gastroenterol. 2012 Jul;28(4):341-8. doi: 10.1097/MOG.0b013e328354567f.
5
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.肿瘤坏死因子拮抗剂治疗克罗恩病的推荐意见：专家共识报告。
Inflamm Bowel Dis. 2012 Jan;18(1):152-60. doi: 10.1002/ibd.21870. Epub 2011 Oct 29.
6
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.早期使用免疫抑制剂或 TNF 拮抗剂治疗克罗恩病：是时候改变了。
Gut. 2011 Dec;60(12):1754-63. doi: 10.1136/gutjnl-2011-300934. Epub 2011 Oct 13.
7
Targeting mucosal healing in Crohn's disease.针对克罗恩病的黏膜愈合
Gastroenterol Hepatol (N Y). 2011 Jun;7(6):374-80.
8
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.基于人群的队列研究中与克罗恩病肠道并发症进展相关的风险因素。
Gastroenterology. 2010 Oct;139(4):1147-55. doi: 10.1053/j.gastro.2010.06.070. Epub 2010 Jul 14.
9
Top-down therapy for IBD: rationale and requisite evidence.IBD 的自上而下治疗：原理和必要证据。
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):86-92. doi: 10.1038/nrgastro.2009.222.
10
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.黏膜愈合可预测克罗恩病患者接受英夫利昔单抗维持治疗的长期疗效。
Inflamm Bowel Dis. 2009 Sep;15(9):1295-301. doi: 10.1002/ibd.20927.
Zotero 插件